Amy Zhang: this ‘underrated’ biotech firm can weather recession


Amy Zhang: this ‘underrated’ biotech firm can weather a recession

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >


Wajeeh Khan

Jun 9, 2022

Amy Zhang picks Bio-Techne as one of her favourite biotech stocks.

She’s convinced the biotech firm can weather the looming recession.

TECH is down more than 30% from its all-time high in September 21.

The iShares Biotechnology ETF (IBB) is still down nearly 25% for the year, but Alger’s portfolio manager says there are opportunities within this space that can weather a recession.

Zhang’s favourite stock in the biotech space

One such name that pops out to Amy Zhang is Bio-Techne Corporation (NASDAQ: TECH) that she says does everything expected of a biotech company. On CNBC’s “Worldwide Exchange”, the portfolio manager said:

Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

We like to invest in companies that save lives, reduce costs, and increase productivity and Bio-Techne does all of that. What’s more unique is that most of their products are very differentiated. So, they have very strong pricing power.

Zhang expects the Minneapolis-headquartered company to do well both in an inflationary as well as a recessionary environment. The stock is down more than 30% from its all-time high in September 2021.

Why else is she bullish on Bio-Techne stock

Last month, Bio-Techne reported its financial results for the first quarter that topped Wall Street expectations. Explaining further why she’s positive on the Nasdaq-listed company, Zhang added:

It’s probably the most underrated gem in life sciences tools and diagnostics space. It’s one of the highest quality compounders that’s very resilient. So, that’s why we really like the company here.

With over 500,000 products, Bio-Techne serves a wide range of markets, including universities, governments, pharmaceutical, and clinical research. Wall Street, on average, sees a more than 40% upside in TECH.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,


75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Visit site


Health & pharmaceuticals


North America

Stocks & Shares




Generated by Feedzy